SCHEMBL7899516

SCHEMBL7899516

COC(=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 5/20 0.63
GRIN3B O60391 5/20 0.63
GRIN1 Q05586 5/20 0.63
GRIN2A Q12879 5/20 0.63
GRIN2B Q13224 5/20 0.63
GRIN2C Q14957 5/20 0.63
GRIN3A Q8TCU5 5/20 0.63
GAA P10253 2/20 0.49
KDM4E B2RXH2 5/20 0.46
GRIA1 P42261 1/20 0.46
GRIA2 P42262 1/20 0.46
GRIA3 P42263 1/20 0.46
GRIA4 P48058 1/20 0.46
GLA P06280 1/20 0.45
MAPT P10636 1/20 0.44
DYRK1A Q13627 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
POLB P06746 2/20 0.42
HTT P42858 1/20 0.42
HPGD P15428 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1721600 0.81 GRIN2D (0.55) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7908962 0.79 GRIN2D (0.54) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL6582728 0.79 KDM4E (0.67) GAAKDM4EGLAMAPTPOLB
SCHEMBL1292034 0.79 GRIN2D (1.00) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL10319865 0.79 DYRK1A (0.61) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL12100557 0.78 GAA (0.46) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL471040 0.78 GRIN2D (0.58) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL10186154 0.77 GRIA1 (0.59) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4512468 0.76 DYRK1A (0.46) GAAKDM4EMAPTDYRK1ADYRK1B
SCHEMBL31336180 0.76 DYRK1A (0.46) GAAKDM4EMAPTDYRK1ADYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2404922-B1 QUINOXALINE COMPOUNDS ASTELLAS PHARMA INC (JP) 2016-11-09 EP disclosed
US-20130085134-A1 QUINOXALINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-04-04 US disclosed
US-8357688-B2 Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors ASTELLAS PHARMA INC. (JP) 2013-01-22 US disclosed
EP-2404922-A1 QUINOXALINE COMPOUNDS Astellas Pharma Inc. (JP) 2012-01-11 EP disclosed
US-20110319385-A1 QUINOXALINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-12-29 US disclosed
WO-2010101230-A1 QUINOXALINE COMPOUNDS アステラス製薬株式会社 (JP) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085134-A1 QUINOXALINE COMPOUND PDE9A, PDE2A, PDE3A GRIN2D 4578/4885GRIN3B 4719/4885GRIN1 4181/4885
US-20110319385-A1 QUINOXALINE COMPOUND PDE9A, PDE5A, PDE3A GRIN2D 4810/4885GRIN3B 4848/4885GRIN1 4685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.